SYN News and Press, Synthetic Biologics Inc. From 08/03/21

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital Updated Agreement Includes Intellectual Property and Technology for Use of SYN-020 Intestinal Alkaline Phosphatase to Inhibit Liver Fibrosis in Select Diseases, Including No...

Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021 Conference Call Scheduled for Thursday, August 5, 2021 at 4:30 p.m. ET PR Newswire ROCKVILLE, Md. , July 28, 2021 /PRNewswire/ -- Synthetic Biol...

Best Biotech Penny Stocks to Watch in July 2021 Biotech penny stocks remain some of the hottest stocks of the year so far. While there are hundreds of penny stocks in the biotech industry to choose from, only a handful have a lot to offer investors of all types. To understand which,...

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 ...

Synthetic Biologics, Inc. (SYN) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Vincent Perrone – Director-Corporate Communication Steven Shallcross – Chief Executive and Financial Officer Michael Kaleko – Senior Vice President-Research and De...

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal ...

Synthetic Biologics (SYN) files for a mixed shelf offering of up to $300M in securities.The filing does not necessarily indicate that a sale has begun, or will occur in the future.Synthetic Biologics are up 0.7% to $0.53 in after-hours trading after closing down 7.3%. For fur...

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 -- Conference Call Scheduled for Wednesday, May 5, 2021 at 4:30 p.m. ET -- PR Newswire ROCKVILLE, Md. , April 28, 2021 /PRNewswire/ -- Synthetic Bio...

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients PR Newswire ROCKVILLE, Md. , April 14, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American...

Biotech Stocks Continue to Lead the Market in Early April 2021 With penny stocks, and specifically biotech penny stocks, there are a few reasons why popularity has increased this year. One of the main factors is the accessibility of trading with platforms like Robinhood and WeBull. This...